Resultados de la búsqueda 281-290 of 11350 for Cycle

1. Programa de tumores cerebrales - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

2. Neurología - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

3. Oncología (médica) - Ensayos clínicos

   ... cycles of mosunetuzumab. An additional arm (open to non-US participants only) has been added to assess the safety, tolerability, pharmacokinetics, and ...

4. Neurología - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

5. Neurocirugía - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

6. Programa de tumores cerebrales - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

7. Ensayos clínicos - Neurología

   The purpose of this study is to assess the safety, tolerability, and effectiveness of additional 6-week treatment cycles with Rozanolixizumab in study ...

8. Oncología (médica) - Ensayos clínicos

   All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   ... cycles of mosunetuzumab. An additional arm (open to non-US participants only) has been added to assess the safety, tolerability, pharmacokinetics, and ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...